Abstract
We appreciate the opportunity to reply to the Letter to the Editor by Dimosiari and colleagues [1], commenting on our work [2]. We concur with them that the cardiovascular disease (CVD) risk of Janus kinase (JAK) inhibitors in patients with ankylosing spondylitis (AS) deserves attention.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.